SBTX News and Press, Silverback Therapeutics Inc. From 11/28/21

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 28, 2021) - Faruqi & Faruqi, LLP, a leading national securities law fi...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options NEW YORK - ( NewMediaWire ) - November 19, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 17, 2021) - Faruqi & Faruqi, LLP, a leading national securities law fi...

New York, New York--(Newsfile Corp. - November 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX) and reminds investors of the January 4, 2022 deadl...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Silverback To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 11, 2021) - Faruqi & Faruqi, LLP, a leading national securities law fi...

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...

Silverback Therapeutics (NASDAQ:SBTX): Q3 GAAP EPS of -$0.65 beats by $0.07. Press Release. For further details see: Silverback Therapeutics EPS beats by $0.07

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...